Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[225Ac]Ac-DOTA-14.G2a is a preclinical targeted alpha therapy (TAT) radiopharmaceutical consisting of the murine anti-ganglioside GD2 monoclonal antibody 14.G2a conjugated to the chelator DOTA and radiolabeled with the alpha-emitting radionuclide actinium-225 ([225Ac]Ac) [EP-0068]. Developed by researchers at the University of British Columbia, TRIUMF, and collaborating institutions, the construct is designed to target GD2, a tumor-associated surface antigen highly expressed in neuroblastoma and other solid tumors. Upon binding to GD2 on cancer cells, the radiopharmaceutical delivers highly localized, high-energy alpha radiation, inducing lethal double-strand DNA breaks in the target cells while minimizing damage to surrounding healthy tissues. Preclinical studies focus on evaluating its biodistribution, intratumoral activity mapping, and the redistribution of its decay daughters (such as bismuth-213) to clearance organs [EP-0068].
| Indication | Highest phase | Status |
|---|---|---|
| neuroblastoma | Preclinical | Active |
| neuroblastoma (MYCN-amplified / non-amplified) | Preclinical | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Lead indication: neuroblastoma
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [225Ac]Ac-DOTA-14.G2a.
Work on [225Ac]Ac-DOTA-14.G2a? Claim this page to correct or add information. Claim this page